Repligen Corp Elects Dr. Jonathan M. Rothberg to Board
Ticker: RGEN · Form: 8-K · Filed: Mar 19, 2024 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $215,000, $17,916, $17,917 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance, personnel
Related Tickers: RGEN
TL;DR
Repligen adds biotech innovator Rothberg to its board.
AI Summary
Repligen Corporation announced on March 18, 2024, that its Board of Directors has elected Dr. Jonathan M. Rothberg as a Class II director, effective immediately. Dr. Rothberg, a prominent figure in life sciences and technology, brings extensive experience to the board. This appointment is part of the company's ongoing efforts to strengthen its leadership and strategic direction.
Why It Matters
The addition of a seasoned innovator like Dr. Rothberg could bring fresh perspectives and strategic guidance to Repligen, potentially impacting its future growth and product development in the life sciences sector.
Risk Assessment
Risk Level: low — The filing is a routine corporate governance update regarding a board appointment and does not involve financial performance or significant operational changes.
Key Players & Entities
- Repligen Corporation (company) — Registrant
- Dr. Jonathan M. Rothberg (person) — Newly Elected Class II Director
- March 18, 2024 (date) — Effective date of board election
FAQ
Who is Dr. Jonathan M. Rothberg and what is his background?
Dr. Jonathan M. Rothberg is a prominent figure in life sciences and technology, bringing extensive experience to the board, though specific details of his background are not elaborated in this filing.
When was Dr. Rothberg's election effective?
Dr. Rothberg's election as a Class II director was effective immediately as of March 18, 2024.
What is the significance of Dr. Rothberg's appointment to Repligen's board?
The appointment is part of Repligen's ongoing efforts to strengthen its leadership and strategic direction, leveraging Dr. Rothberg's experience in life sciences and technology.
What class of director was Dr. Rothberg elected as?
Dr. Rothberg was elected as a Class II director.
What other items are typically included in an 8-K filing of this nature?
This 8-K filing also includes information on Regulation FD Disclosure and Financial Statements and Exhibits, in addition to the director appointment.
Filing Stats: 927 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2024-03-19 07:41:02
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share RGEN The Nasdaq Global Se
- $215,000 — mmon stock having an aggregate value of $215,000 (the "Initial Board Option"). The Initi
- $17,916 — mmon stock having an aggregate value of $17,916 and (2) restricted stock units having a
- $17,917 — tock units having an aggregate value of $17,917 (together, the "Pro-Rata Award"), refle
Filing Documents
- d768236d8k.htm (8-K) — 28KB
- d768236dex991.htm (EX-99.1) — 9KB
- g768236g0319061252300.jpg (GRAPHIC) — 5KB
- 0001193125-24-070768.txt ( ) — 172KB
- rgen-20240318.xsd (EX-101.SCH) — 3KB
- rgen-20240318_lab.xml (EX-101.LAB) — 18KB
- rgen-20240318_pre.xml (EX-101.PRE) — 11KB
- d768236d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Repligen Corporation on March 19, 2024. 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Dated: March 19, 2024 By: /s/ Tony J. Hunt Tony J. Hunt Chief Executive Officer